epilepsy-istock-636332090-sudok1-
sudok1 / iStockphoto.com
4 February 2019Americas

Fed Circuit rules against Mylan in patent dispute over epilepsy drug

Generic-drug manufacturers Mylan Pharmaceuticals, Breckenridge Pharmaceutical and Alembin Pharmaceuticals have lost their bid to prove that claims in a patent owned by US company Research Corporation Technologies, were invalid on the grounds of obviousness.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
27 March 2017   The Patent Trial and Appeal Board has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat in a case brought by Argentum Pharmaceuticals.

More on this story

Americas
27 March 2017   The Patent Trial and Appeal Board has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat in a case brought by Argentum Pharmaceuticals.

More on this story

Americas
27 March 2017   The Patent Trial and Appeal Board has upheld a Research Corporation Technologies patent for anti-epileptic drug Vimpat in a case brought by Argentum Pharmaceuticals.